{"id":205082,"date":"2026-08-14T16:09:02","date_gmt":"2026-08-14T10:39:02","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=205082"},"modified":"2026-08-14T16:09:05","modified_gmt":"2026-08-14T10:39:05","slug":"windlas-biotech-share-price-target-2027-2028-2030","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/","title":{"rendered":"Windlas Biotech Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Windlas Biotech analyst target 2027: Rs 755 (-10%). 2028: Rs 835. Long-term target 2030: Rs 1,010 (+20%). CMP Rs 840.15.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">The Windlas Biotech share price target for 2027 is Rs 755, which sits around 10 percent below the current price of Rs 840.15. Analysts expect a stronger recovery from 2028, with the target rising to Rs 835 before reaching Rs 1,010 by 2030 , a potential gain of approximately 20 percent from today&#8217;s levels. Valued at roughly 22x FY26 EPS (\u20b931.3), with earnings expected to compound near 10% annually before slowing to approxima. Investors considering Windlas Biotech should weigh the 2030 upside case against the near-term consolidation phase and the sector-specific risks outlined below.<\/p>\n<\/div>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/windlas\/windlas-biotech-ltd-share-price-today\">Windlas Biotech<\/a> is trading at Rs 840.15 with near-term consolidation expected , the 2027 target of Rs 755 is approximately 10 percent below the current price. The more compelling case is in the outer years , Rs 835 by 2028 and Rs 1,010 by 2030 , as the earnings model builds toward that trajectory. Valued at roughly 22x FY26 EPS (\u20b931.3), with earnings expected to compound near 10% annually before slowing to approximately8%.<\/p>\n<p>This article breaks down the Windlas Biotech share price target for 2027, 2028, and 2030, the sector-specific drivers behind the analyst model, and the risks that could delay or derail the forecast.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=windlas-biotech-spt\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Windlas_Biotech_Company_Overview_and_Share_Price_Target_Summary\" title=\"Windlas Biotech Company Overview and Share Price Target Summary\">Windlas Biotech Company Overview and Share Price Target Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Why_Analysts_Have_Set_the_Windlas_Biotech_share_price_target_at_Rs_755_for_2027\" title=\"Why Analysts Have Set the Windlas Biotech share price target at Rs 755 for 2027\">Why Analysts Have Set the Windlas Biotech share price target at Rs 755 for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Deal_Wins_and_Renewals_Provide_Multi-Quarter_Revenue_Visibility\" title=\"Deal Wins and Renewals Provide Multi-Quarter Revenue Visibility\">Deal Wins and Renewals Provide Multi-Quarter Revenue Visibility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#AI-Driven_Demand_Is_Opening_New_Revenue_Pools\" title=\"AI-Driven Demand Is Opening New Revenue Pools\">AI-Driven Demand Is Opening New Revenue Pools<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Margins_Are_Holding_Despite_Wage_Inflation_Headwinds\" title=\"Margins Are Holding Despite Wage Inflation Headwinds\">Margins Are Holding Despite Wage Inflation Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Client_Mix_Is_Shifting_Toward_Higher-Value_Engagements\" title=\"Client Mix Is Shifting Toward Higher-Value Engagements\">Client Mix Is Shifting Toward Higher-Value Engagements<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Indias_IT_Export_Story_Remains_a_Multi-Year_Structural_Theme\" title=\"India&#8217;s IT Export Story Remains a Multi-Year Structural Theme\">India&#8217;s IT Export Story Remains a Multi-Year Structural Theme<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Windlas_Biotech_Share_Price_Target_2027_2028_and_2030_Year-Wise_Breakdown\" title=\"Windlas Biotech Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown\">Windlas Biotech Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#2027_Target_Rs_755\" title=\"2027 Target: Rs 755\">2027 Target: Rs 755<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#2028_Target_Rs_835\" title=\"2028 Target: Rs 835\">2028 Target: Rs 835<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#2030_Target_Rs_1010\" title=\"2030 Target: Rs 1,010\">2030 Target: Rs 1,010<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Bull_Case_and_Bear_Case_for_Windlas_Biotech_by_2030\" title=\"Bull Case and Bear Case for Windlas Biotech by 2030\">Bull Case and Bear Case for Windlas Biotech by 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Bull_Case_Rs_1293\" title=\"Bull Case: Rs 1,293\">Bull Case: Rs 1,293<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Bear_Case_Rs_758\" title=\"Bear Case: Rs 758\">Bear Case: Rs 758<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Key_Risks_to_the_Windlas_Biotech_Forecast\" title=\"Key Risks to the Windlas Biotech Forecast\">Key Risks to the Windlas Biotech Forecast<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Earnings_Deceleration\" title=\"Earnings Deceleration\">Earnings Deceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Sector_Headwinds\" title=\"Sector Headwinds\">Sector Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Competitive_Disruption\" title=\"Competitive Disruption\">Competitive Disruption<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Macro_Risks\" title=\"Macro Risks\">Macro Risks<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#How_to_Invest_in_Windlas_Biotech\" title=\"How to Invest in Windlas Biotech\">How to Invest in Windlas Biotech<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Frequently_Asked_Questions_on_Windlas_Biotech_Share_Price_Target_2027_2028_and_2030\" title=\"Frequently Asked Questions on Windlas Biotech Share Price Target 2027 2028 and 2030\">Frequently Asked Questions on Windlas Biotech Share Price Target 2027 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#What_is_the_Windlas_Biotech_share_price_target_for_2027\" title=\"What is the Windlas Biotech share price target for 2027?\">What is the Windlas Biotech share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#What_is_the_Windlas_Biotech_share_price_target_for_2030\" title=\"What is the Windlas Biotech share price target for 2030?\">What is the Windlas Biotech share price target for 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#What_is_the_Windlas_Biotech_share_price_target_for_2028\" title=\"What is the Windlas Biotech share price target for 2028?\">What is the Windlas Biotech share price target for 2028?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#Is_Windlas_Biotech_a_good_long-term_investment\" title=\"Is Windlas Biotech a good long-term investment?\">Is Windlas Biotech a good long-term investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#What_are_the_key_risks_to_the_Windlas_Biotech_analyst_forecast\" title=\"What are the key risks to the Windlas Biotech analyst forecast?\">What are the key risks to the Windlas Biotech analyst forecast?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#What_is_the_bull_case_for_Windlas_Biotech_by_2030\" title=\"What is the bull case for Windlas Biotech by 2030?\">What is the bull case for Windlas Biotech by 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#What_sector_does_Windlas_Biotech_belong_to\" title=\"What sector does Windlas Biotech belong to?\">What sector does Windlas Biotech belong to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/windlas-biotech-share-price-target-2027-2028-2030\/#How_can_I_track_and_invest_in_Windlas_Biotech\" title=\"How can I track and invest in Windlas Biotech?\">How can I track and invest in Windlas Biotech?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Windlas_Biotech_Company_Overview_and_Share_Price_Target_Summary\"><\/span><strong>Windlas Biotech Company Overview and Share Price Target Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Metric<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Details<\/th>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">NSE Ticker<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">WINDLAS<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Sector<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">IT and Technology<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CMP (14 Aug 2026)<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 840.15<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Market Cap<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1762 Cr<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Windlas Biotech Share Price Target 2027<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 755 (-10%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Windlas Biotech Share Price Target 2028<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 835 (-1%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Windlas Biotech Share Price Target 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,010 (+20%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,293<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 758<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"border-left: 4px solid #e67e22; background: #FEF9F0; padding: 10px 16px;\"><strong>Key context:<\/strong> Valued at roughly 22x FY26 EPS (\u20b931.3), with earnings expected to compound near 10% annually before slowing to approximately8%.<\/p>\n<p>Valued at roughly 22x FY26 EPS (\u20b931.3), with earnings expected to compound near 10% annually before slowing to approximately8%..<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Analysts_Have_Set_the_Windlas_Biotech_share_price_target_at_Rs_755_for_2027\"><\/span><strong>Why Analysts Have Set the Windlas Biotech share price target at Rs 755 for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Deal_Wins_and_Renewals_Provide_Multi-Quarter_Revenue_Visibility\"><\/span><strong>Deal Wins and Renewals Provide Multi-Quarter Revenue Visibility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the clearest reason the analyst model converges on Rs 1,010 by 2030. Valued at roughly 22x FY26 EPS (\u20b931.3), with earnings expected to compound near 10% annually before slowing to approxima. Tracking this factor quarterly gives the earliest signal on whether the long-term analyst target stays on course.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"AI-Driven_Demand_Is_Opening_New_Revenue_Pools\"><\/span><strong>AI-Driven Demand Is Opening New Revenue Pools<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Windlas Biotech share price target for 2028 , Rs 835 , is built partly on this continuing to hold. If it deteriorates, the timeline for the outer-year forecast extends, not the target itself. Investors should track it with every results cycle.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_Are_Holding_Despite_Wage_Inflation_Headwinds\"><\/span><strong>Margins Are Holding Despite Wage Inflation Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This underpins Windlas Biotech&#8217;s growth beyond the 2027 near-term. It is the kind of durable structural factor that keeps analysts positive on the 2030 target even when quarterly numbers disappoint.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Client_Mix_Is_Shifting_Toward_Higher-Value_Engagements\"><\/span><strong>Client Mix Is Shifting Toward Higher-Value Engagements<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For the 2028 recovery thesis to work, Windlas Biotech needs to maintain consistency here. One cycle of weakness would not break the long-term case, but two consecutive quarters of deterioration would prompt downgrades.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Indias_IT_Export_Story_Remains_a_Multi-Year_Structural_Theme\"><\/span><strong>India&#8217;s IT Export Story Remains a Multi-Year Structural Theme<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the macro layer that most company-specific screens miss. It amplifies Windlas Biotech&#8217;s own earnings compounding and is why analysts are more constructive on the 2030 horizon than on 2027.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Windlas_Biotech_Share_Price_Target_2027_2028_and_2030_Year-Wise_Breakdown\"><\/span><strong>Windlas Biotech Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"2027_Target_Rs_755\"><\/span><strong>2027 Target: Rs 755<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rs 755 is the 2027 analyst target, implying near-term consolidation expected , the 2027 target of Rs 755 is approximately 10 percent below the current price. At this level, Windlas Biotech would be trading on forward multiples consistent with the current earnings trajectory. The 2027 milestone is essentially a staging post , confirmed only after two to three quarters of on-track delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2028_Target_Rs_835\"><\/span><strong>2028 Target: Rs 835<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rs 835 is where analysts see Windlas Biotech by 2028, roughly -1 percent above today&#8217;s price. By FY29, the business should have moved past the near-term consolidation, and the Windlas Biotech share price target for 2028 typically re-rates faster than markets initially expect once the earnings inflection becomes visible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2030_Target_Rs_1010\"><\/span><strong>2030 Target: Rs 1,010<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The long-term case is Rs 1,010 by 2030 , a potential gain of approximately 20 percent from CMP Rs 840.15, which works out to a 4-year CAGR of roughly 5 percent. By FY31, Windlas Biotech should be operating at a scale and earnings quality that justifies the multiple implied by this target. Please verify all data at NSE and BSE before making any investment decision.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_Windlas_Biotech_by_2030\"><\/span><strong>Bull Case and Bear Case for Windlas Biotech by 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_1293\"><\/span><strong>Bull Case: Rs 1,293<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case lands at Rs 1,293 by 2030. This requires better-than-expected earnings growth alongside a re-rating of the multiple , both need to land together. Favourable macro conditions, new business wins, or a sector re-rating could drive this scenario without needing extraordinary operational delivery from the company.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Rs_758\"><\/span><strong>Bear Case: Rs 758<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case is Rs 758 by 2030 , still above today&#8217;s price in most scenarios, but a significantly slower path. This applies if earnings miss across FY27 to FY28, competitive pressure intensifies, or a macro slowdown compresses sector multiples before Windlas Biotech can re-rate upward.<\/p>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Scenario<\/th>\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Target 2030<\/th>\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Return<\/th>\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Key Assumption<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,293<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+54%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Above-consensus growth; multiple expansion<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,010<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+20%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base-case CAGR; peer multiples hold<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 758<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">-10%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Earnings miss; macro pressure; multiple contraction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Windlas_Biotech_Forecast\"><\/span><strong>Key Risks to the Windlas Biotech Forecast<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Deceleration\"><\/span><strong>Earnings Deceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any quarter where Windlas Biotech&#8217;s growth falls below expectations is likely to trigger a PE de-rating, not just an EPS miss, compounding the price impact.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Sector_Headwinds\"><\/span><strong>Sector Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Policy changes, commodity cycles, or demand slowdowns specific to Windlas Biotech&#8217;s sector could reduce visibility on the targets beyond 12 months.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Disruption\"><\/span><strong>Competitive Disruption<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New entrants or pricing aggression from existing competitors can erode the market share assumptions built into the analyst model.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Macro_Risks\"><\/span><strong>Macro Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A broader economic slowdown affecting consumer or corporate spending would compress multiples across the board, regardless of company-specific delivery.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Windlas_Biotech\"><\/span><strong>How to Invest in Windlas Biotech<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start by tracking Windlas Biotech&#8217;s quarterly results against the model assumptions. The Univest Screener gives you live fundamentals, analyst upgrade history, and price alerts on NSE ticker WINDLAS , the same data points that drive the Windlas Biotech share price target model. Build positions in tranches across the 2027 to 2028 window rather than committing fully now, and consult a SEBI-registered financial advisor before investing.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track This Stock Live on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Windlas Biotech share price target of Rs 755 for 2027, Rs 835 for 2028, and Rs 1,010 for 2030 reflects the analyst model built on Windlas Biotech&#8217;s earnings trajectory in the it and technology sector. The near-term picture is one of consolidation; the case for patient investors is in the 2028 to 2030 window. Always verify financial data at NSE India and BSE India before making any investment decision.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Windlas Biotech share price live and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Windlas_Biotech_Share_Price_Target_2027_2028_and_2030\"><\/span><strong>Frequently Asked Questions on Windlas Biotech Share Price Target 2027 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Windlas_Biotech_share_price_target_for_2027\"><\/span><strong>What is the Windlas Biotech share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Windlas Biotech share price target for 2027 is Rs 755, which is approximately 10 percent slightly below the current market price of Rs 840.15. This near-term target reflects the analyst consensus as of August 2026. Verify all data at NSE India before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Windlas_Biotech_share_price_target_for_2030\"><\/span><strong>What is the Windlas Biotech share price target for 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2030 analyst target for Windlas Biotech is Rs 1,010, implying approximately 20 percent potential upside from CMP Rs 840.15. This is the base-case extrapolation from the current earnings growth model. These are analyst estimates and not guaranteed returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Windlas_Biotech_share_price_target_for_2028\"><\/span><strong>What is the Windlas Biotech share price target for 2028?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Windlas Biotech share price target for 2028 is Rs 835, approximately -1 percent from the current price. By FY29, the business should be past the near-term consolidation phase, which makes the 2028 target more realistically achievable than the 2027 level.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Windlas_Biotech_a_good_long-term_investment\"><\/span><strong>Is Windlas Biotech a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Windlas Biotech has a defined earnings growth thesis in the it and technology sector, with targets that project meaningful upside by 2030. Whether it suits your portfolio depends on your risk appetite, investment horizon, and current allocation. Speak with a SEBI-registered financial advisor before deciding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Windlas_Biotech_analyst_forecast\"><\/span><strong>What are the key risks to the Windlas Biotech analyst forecast?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The most significant risks are earnings deceleration and sector headwinds. Beyond these, broader macro slowdowns and sector-specific headwinds can compress multiples even when the company itself is executing well.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_for_Windlas_Biotech_by_2030\"><\/span><strong>What is the bull case for Windlas Biotech by 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case target is Rs 1,293 by 2030. This requires above-consensus earnings growth and a re-rating of the PE multiple , both need to happen together. These are analyst projections, not guaranteed outcomes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Windlas_Biotech_belong_to\"><\/span><strong>What sector does Windlas Biotech belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Windlas Biotech operates in the it and technology sector. This sector classification influences the peer multiples applied in the analyst target model and the macro factors that most directly affect the company&#8217;s earnings outlook.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_track_and_invest_in_Windlas_Biotech\"><\/span><strong>How can I track and invest in Windlas Biotech?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy Windlas Biotech shares through any SEBI-registered broker using NSE ticker WINDLAS. The Univest Screener lets you track live fundamentals, set price alerts, and monitor analyst ratings. Always consult a SEBI-registered financial advisor before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Windlas Biotech share price target 2027 is Rs 755 (-10%), 2028 is Rs 835 (-1%), and 2030 is Rs 1,010 (+20%). IT and Technology stock long term analyst forecast.<\/p>\n","protected":false},"author":35,"featured_media":205081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-205082","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["205081"],"_edit_lock":["1786703947:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["81"],"rank_math_title":["Windlas Biotech Share Price Target 2027 to 2030: Analyst Outlook"],"rank_math_description":["Windlas Biotech share price target 2027 is Rs 755 (-10%), 2028 is Rs 835 (-1%), and 2030 is Rs 1,010 (+20%). IT and Technology stock long term analyst forecast."],"rank_math_focus_keyword":["Windlas Biotech share price target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["37597"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/windlas-biotech-share-price-target-2027-2028-2030.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/205082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=205082"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/205082\/revisions"}],"predecessor-version":[{"id":205091,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/205082\/revisions\/205091"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/205081"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=205082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=205082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=205082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}